A buyout rumor has investors hopeful.
News & Analysis: The Medicines Company
Clinical data for cholesterol-lowering drug inclisiran looks good.
MDCO earnings call for the period ending September 30, 2019.
The company's flagship cholesterol treatment shows major potential.
The Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's Success
Investors should go to the source.
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
On a day when trade worries and weak economic data hurt stocks, Medicines Company rose on a successful drug trial and Boston Beer fell following a downgrade.
A detailed look at a big clinical trial did not disappoint.
These stocks managed to overcome a big market downdraft.
The biotech got good news on a clinical trial.